[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342287-105":59,"doc-detail-342287-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nuclear-dux4-immunohistochemistry-is-a-highly-sensitive-and-specific-marker-for-the-presence-of-cicdux4-fusion-in-cic-rearranged-sarcomas-a-study-of-48-molecularly-confirmed-cases","Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC::DUX4 fusion in CIC-rearranged sarcomas - a study of 48 molecularly confirmed cases","","Nuclear DUX4 immunohistochemistry (IHC) was evaluated as a surrogate for CIC::DUX4 fusion detection in clinically aggressive CIC-rearranged sarcomas (CRS), where DUX4 breakpoint variability can limit molecular identification. The study analyzed 48 molecularly confirmed CRS cases and 105 non-CRS controls, testing DUX4 IHC positivity by strong nuclear staining in over half of tumor cells. Sensitivity and specificity for CRS diagnosis were 98% and 100%, with one CRS case negative by IHC but harboring a CIC::FOXO4 fusion.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nuclear-dux4-immunohistochemistry-is-a-highly-sensitive-and-specific-marker-for-the-presence-of-cicdux4-fusion-in-cic-rearranged-sarcomas-a-study-of-48-molecularly-confirmed-cases/342287/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nuclear-dux4-immunohistochemistry-is-a-highly-sensitive-and-specific-marker-for-the-presence-of-cicdux4-fusion-in-cic-rearranged-sarcomas-a-study-of-48-molecularly-confirmed-cases/342287.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address for diagnosing CRS?","Question",{"text":112,"@type":113},"CRS diagnosis can miss CIC::DUX4 fusion when molecular testing fails due to DUX4 repetitiveness and variable fusion breakpoints. The study evaluates whether DUX4 IHC can serve as a reliable surrogate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DUX4 IHC positivity defined in the study?",{"text":117,"@type":113},"DUX4 IHC was considered positive when strong nuclear expression was detected in more than 50% of neoplastic cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic performance did DUX4 IHC show for CRS?",{"text":121,"@type":113},"Used as a surrogate for CRS diagnosis, DUX4 IHC achieved 98% sensitivity and 100% specificity in this cohort.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342287,1791179153,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Histopathology 2025, 86, 423–432. DOI: 10.1111/his.15341  \nNuclear DUX4 immunohistochemistry is a highly sensitive and speciﬁc marker for the presence of CIC::DUX4 fusion in CIC-rearranged sarcomas: a study of 48 molecularlyconﬁrmed cases  \nRodrigo T Macedo, 1 Vira Baranovska-Andrigo,2 Tams Pancsa,2,3 Natlie Klubkov ,2,3 Brian P Rubin,1 Scott E Kilpatrick,1 John R Goldblum,1 Karen J Fritchie,1 Steven D Billings,1 Michal Michal,2,3 Marin vajdler,2,3 Zdenk Kinkor,3 Michael Michal2,3,† &  \nJosephine K Dermawan1,†  \n1Department of Pathology and Laboratory Medicine, Diagnostic Institute, Cleveland Clinic, Cleveland, OH, USA, 2Department of Pathology, Charles University, Faculty of Medicine in Pilsen and 3Biopticka laborator Ltd, Pilsen, Czech Republic  \nDate of submission 29 July 2024  \nAccepted for publication 19 September 2024  \nMacedo R T, Baranovska-Andrigo V, Pancsa T, Klubkov N, Rubin B P, Kilpatrick S E, Goldblum J R,  \n􀀃  \nFritchie K J, Billings S D, Michal M, Svajdler M, Kinkor Z, Michal M & Dermawan J K (2025) Histopathology 86, 423–432. [https://doi.org/10.1111/his.15341](https://doi.org/10.1111/his.15341)  \nNuclear DUX4 immunohistochemistry is a highly sensitive and speciﬁc marker for the presence of CIC::DUX4 fusion in CIC-rearranged sarcomas: a study of 48 molecularlyconﬁrmed cases  \nAims: CIC-rearranged sarcomas (CRS) are clinically aggressive undifferentiated round cell sarcomas (URCS), commonly driven by CIC::DUX4 . Due to the repetitive nature of DUX4 and the variability of the fusion breakpoints, CIC::DUX4 fusion may be missed by molecular testing. Immunohistochemical (IHC) stains have been studied as surrogates for the CIC:: DUX4 fusion. We aim to assess the performance of DUX4 IHC in the work-up of CRS and its expression in non-CRS round cell or epithelioid neoplasms. Methods and results: Cases of molecularly conﬁrmed CRS (n = 48) and non-CRS (n = 105) were included. CRS cases consisted of 35 females and 13 males, with ages ranging from less than 1 year to 67 years (median = 41 years) . Among the molecularly conﬁrmed non-CRS cases, C-terminal DUX4 expression was investigated in Ewing sarcomas (38 cases), alveolar  \nrhabdomyosarcomas (18 cases), desmoplastic small round cell tumours (12 cases) and synovial sarcomas (n = ﬁve), as well as in non-mesenchymal neoplasms such as SMARCA4/SMARCB1-deﬁcient tumours (n = ﬁve), carcinomas of unknown primary (n = three) and haematolymphoid neoplasms (four cases) . DUX4 IHC was considered positive when strong nuclear expression was detected in more than 50% of neoplastic cells. When used as a surrogate for the diagnosis of CRS, the sensitivity and speciﬁcity of DUX4 IHC was 98 and 100%, respectively. Only one CRS case was negative for DUX4 IHC and harboureda CIC::FOXO4 fusion.  \nConclusions: DUX4 IHC is a highly sensitive and speciﬁc surrogate marker for the presence of CIC::DUX4 fusion, demonstrating its utility in establishing a diagnosis of CRS.  \nAddress for correspondence: J Dermawan, Department of Pathology and Laboratory Medicine, Diagnostic Institute, Cleveland Clinic, Cleve  \nland, OH 44194, USA. e-mail: [dermawj@ccf.org](dermawj@ccf.org)  \n†Co-senior authors.  \nAbbreviations: CRS, CIC-rearranged sarcomas; FISH, ﬂuorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; URCS, undifferentiated round cell sarcomas.  \n􀀁 2024 The Author(s) . Histopathology published by John Wiley & Sons Ltd.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.  \n424 R T Macedo et al.  \nKeywords: CIC::DUX4 , CIC-rearranged sarcomas, immunohistochemistry, round cell sarcoma, small round cell tumours  \nIntroduction  \nUndifferentiated round cell sarcomas (URCS) comprise a category of malignant mesenchymal tumours with histologica","cbCaiquKLHvHDVW3","https://ap.wps.com/l/cbCaiquKLHvHDVW3","pdf",1853811,"English","# Aims\n# Methods and results\n# Conclusions\n# Keywords\n## Abbreviations","[{\"question\":\"What problem does the study address for diagnosing CRS?\",\"answer\":\"CRS diagnosis can miss CIC::DUX4 fusion when molecular testing fails due to DUX4 repetitiveness and variable fusion breakpoints. The study evaluates whether DUX4 IHC can serve as a reliable surrogate.\"},{\"question\":\"How was DUX4 IHC positivity defined in the study?\",\"answer\":\"DUX4 IHC was considered positive when strong nuclear expression was detected in more than 50% of neoplastic cells.\"},{\"question\":\"What diagnostic performance did DUX4 IHC show for CRS?\",\"answer\":\"Used as a surrogate for CRS diagnosis, DUX4 IHC achieved 98% sensitivity and 100% specificity in this cohort.\"}]","Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC::DUX4 fusion in CIC-rearranged sarcomas - a study of 48 molecularly confirmed cases | PDF",1790046021,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f19e49d0cc77fb0518deda56cb949e73.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed56c694e375e3e1593cd00a0976e4d6.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67160963a52419560e448436a6ed50db.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bccd4d0b7d92685dba873c853ea12393.webp",980,1287]